---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-22-000055"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:29:23.334698+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moderna and Merck report Phase 2b mRNA cancer vaccine met primary endpoint in melanoma, reducing recurrence risk by 44%

## Summary
- mRNA-4157/V940 + KEYTRUDA reduced risk of recurrence or death by 44% vs KEYTRUDA alone (HR=0.56, p=0.0266) in stage III/IV melanoma.
- First randomized trial evidence for an mRNA cancer treatment; companies plan Phase 3 in melanoma in 2023 and expansion to other tumor types.
- Serious treatment-related AEs: 14.4% in combination arm vs 10% with KEYTRUDA alone.
- Merck and Moderna share costs and profits equally under worldwide collaboration announced in October.

## SEC filing metadata
- accession: 0001682852-22-000055
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285222000055/0001682852-22-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285222000055/mrna-20221213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-22-000055
- JSON: https://secwatch.observer/filing/0001682852-22-000055.json
- Plain text: https://secwatch.observer/filing/0001682852-22-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.